BIMERVAX LP.8.1 emulsion for injection COVID-19 Vaccine (recombinant

DRUG2 trials

Sponsors

Hipra Scientific S.L.

Conditions

COVID-19

Phase 4

A Phase IV, open label, single arm trial to assess the safety and immunogenicity of BIMERVAX® LP.8.1 against SARS-CoV-2 variants.

CompletedCTIS2025-524021-41-00

Hipra Scientific S.L.COVID-19

Start: 2025-10-28End: 2026-01-08Target: 68Updated: 2025-12-10

A Phase IV, open label, single arm trial to assess the safety and immunogenicity of BIMERVAX® XFG.1.1 against SARS-CoV-2 Omicron XFG.1.1 variant.

Not yet recruitingCTIS2026-527363-16-00

Hipra Scientific S.L.COVID-19

Target: 70Updated: 2026-09-07